Dr Reddy’s Laboratories reported a modest 2% year-on-year increase in net profit at ₹1,418 crore for the April–June quarter. Revenue, however, jumped a solid 11.4% to ₹8,545 crore compared to ₹7,672.7 crore in the same period last year.
This indicates a strong topline performance, even though the bottom line growth was limited due to rising operational expenses.
Mixed Regional Performance
One key concern for investors is the 11% year-on-year decline in North American sales, which fell to ₹3,410 crore from ₹3,846 crore. This dip came despite overall revenue growth and may be due to pricing pressure and higher competition in the US market.
Also Read: Indiqube Spaces IPO: Should you invest? Check GMP and review by experts
India & Emerging Markets Cushion the Blow
While US sales dipped, strong performance in India and emerging markets helped balance the overall numbers. The domestic market and other international regions continued to show resilience.
Dr Reddy’s delivered steady revenue growth, but profit was weighed down by rising costs and weaker US performance. Long-term investors may want to watch future quarters for improvement in the US market and margin recovery.
Click here to explore other: DR. REDDY’S LABORATORIES Stock Price
